falsefalse

Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLC - Episode 5

Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC

,

Panelists discuss how medical professionals consider continuing osimertinib with second-line and subsequent therapies based on disease progression, resistance mechanisms, and patient response. It may be combined with other agents or switched depending on clinical trials, biomarkers, and overall treatment goals to optimize outcomes.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC
    EP. 2: EGFR-Mutated NSCLC Disease Risk Stratification
    EP. 3: Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC
    EP. 4: Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
    Now Viewing
    EP. 5: Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC
    EP. 6: Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC
    EP. 7: Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC
    EP. 8: Future Treatment Options in EGFR-Mutant NSCLC

    Video content above is prompted by the following:

    What are your thoughts on continuing osimertinib treatment with second-line and subsequent therapies?

    Related Content:

    Critical Decision Points When Selecting EGFR-Targeted Therapy for NSCLCVideo SeriesClinicalLung Cancer
    Dr Saxena on the Evolving Utility of Targeted Therapies for ALK+ NSCLC
    Tarlatamab Yields OS Improvement in SCLC After Platinum Progression
    Health Canada Approves Durvalumab Monotherapy for Limited-Stage Small Cell Lung Cancer
    x